Actavis to launch 20 new drugs in Serbia - Production capacities doubled

This year, pharmaceutical company, Actavis will launch 20 new drugs in cardiology, psychiatry, neurology and gynecology.

The head of Actavis for Serbia, Montenegro and Adria region, dr. Pavle Marjanovic, estimates the start of 2015 as turbulent and challenging for pharmaceutical industry in Serbia due to dramatic fall of drugs prices as well as unaligned foreign currency calculation rate with real one. Thanks to implementation of new products from Actavis portfolio and new exporting business, production capacities in Leskovac-based Zdravlje which opened 100 new vacancies almost doubled, dr. Marjanovic says.

- Thanks to understanding of drug producers which accepted to supply the state at significantly lower prices, significant budget savings in 2015 will be generated. It would be very important to use these savings for implementation of modern therapies, expansion of circle of patients who need treatment and introduction of drugs which are not available now – Marjanovic says, adding that it seems to him it does not happen now despite the fact that funds for drugs in Serbia have been among the lowest in Europe.

- Average drug price was lower in Serbia than for instance in Bosnia and Herzegovina, almost double the amount lower than in Croatia and three times lower than in Slovenia. I am sure that through partnership dialog of drugs producers and the state, the best solution will be found for patients in Serbia and that we will use the opportunity to improve health protection quality–Marjanovic says.

Zdravlje a.d. Leskovac

Actavis Beograd

Actavis Srbija

Zdravlje Leskovac

Ravle Marjanović

drug production

psychiatry

neurology

gynecology

drugs prices